GSK's Nucala (mepolizumab) has shown positive results in an advanced trial for treating chronic obstructive pulmonary disease (COPD), potentially expanding the drug's application beyond asthma. The study demonstrated a statistically significant and clinically meaningful reduction in the rate of moderate and severe flare-ups in COPD patients compared to placebo.
Clinical Trial Details
The trial involved 806 adult patients with COPD who were treated with Nucala for up to two years. Nucala, a monoclonal antibody, was administered in addition to inhaled maintenance therapy. GSK reported that the study met its primary endpoint, showing a notable decrease in the frequency of COPD exacerbations. Full results from the study are expected to be published at a later date.
Impact on COPD Treatment
COPD is a life-threatening inflammatory respiratory disease affecting over 300 million people globally. Recurrent exacerbations can lead to lung damage, hospitalization, and a decline in overall health, quality of life, and increased mortality. Until recently, there had been limited new treatment approaches for COPD for over a decade. Sanofi’s Dupixent was recently approved in Europe as an add-on treatment for some COPD patients.
Nucala's Background and Market Performance
Nucala was first approved in the US in 2015 for severe asthma and has become a top-performing drug for GSK, generating £1.7 billion ($2.24 billion) in sales last year. The potential expansion into COPD treatment represents a significant opportunity for further growth.
GSK's Perspective
GSK noted that the reduction in flare-ups is crucial for COPD patients, as these exacerbations can create a vicious cycle of deteriorating health. The company believes Nucala could offer a valuable new option for managing this condition. GSK shares were relatively stable following the announcement, reflecting a year-to-date increase of 19%.
